First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon(Peter MacCallum Cancer Centre), Fiona Blackhall(University of Manchester), Jolanda Paolini(Pfizer (Italy)), Shrividya Iyer(Pfizer (United States)), Tiziana Usari(Pfizer (Italy)), Keith D. Wilner(Pfizer (United States)), Jennifer Tursi(Endo Pharmaceuticals (United States)), Tony Mok(Chinese University of Hong Kong), Enriqueta Felip(Institut Català d'Ornitologia), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Dong‐Wan Kim(Seoul National University Hospital), Federico Cappuzzo(Ospedale di Livorno), Tarek Mekhail(AdventHealth Orlando), Arlene Reisman(Pfizer (United States))
Cited by 3,209
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k